Towards Healthcare

Viral Vector and Plasmid DNA Manufacturing Companies Strategic Expansion Initiatives, Revenue Diversification, Strategic Joint Ventures

Date: January 2025

Viral Vector and Plasmid DNA Manufacturing Manufacturers and Market Growth

The global viral vector and plasmid DNA manufacturing market size was estimated at US$ 6.01 billion in 2023 and is projected to grow to US$ 43.04 billion by 2034, rising at a compound annual growth rate (CAGR) of 20.7% from 2024 to 2034.

Top Companies in the Viral Vector and Plasmid DNA Manufacturing

  • Merck KGaA
  • ProBio Inc.
  • Audentes Therapeutics
  • Lonza
  • Asahi Kasei
  • FUJIFILM Diosynth Biotechnologies
  • Cobra Biologics
  • Genezen laboratories
  • SIRION Biotech GmbH
  • Thermo Fisher Scientific
  • Catalent Inc.
  • Wuxi Biologics
  • Batavia Biosciences
  • Takara Bio Inc.
  • Virovek Incorporation
  • Waisman Biomanufacturing
  • Miltenyi Biotec GmbH
  • BioNTech IMFS GmbH
  • RegenxBio, Inc.
  • BioMarin Pharmaceutical

ProBio in the Viral Vector and Plasmid DNA Manufacturing Market

Company Name ProBio Inc.
Headquarters New Jersey, U.S., North America
Recent Development In June 2024, a new, state-of-the-art facility in Hopewell, New Jersey, allowed ProBio Inc., a contract development and manufacturing organization (CDMO) located in New Jersey, to expand its manufacturing capabilities for viral vectors and plasmid DNA. The production of life-altering cell and gene treatments in North America will be greatly aided by ProBio's new, state-of-the-art facility, which will operate as the center of operations for its activities in the region.

Asahi Kasei in the Viral Vector and Plasmid DNA Manufacturing Market

Company Name Asahi Kasei Corporation
Headquarters Tokyo, Japan, Asia Pacific
Recent Development In June 2024, the full-service biologics CDMO Bionova Scientific, a US subsidiary of Asahi Kasei Medical, made the decision to open a new business line offering services utilizing plasmid DNA and to construct a facility specifically for this purpose in Texas.

Recent Developments in the Viral Vector and Plasmid DNA Manufacturing Market

  • In July 2024, 1 kilogram of plasmid DNA was produced in a single batch for a significant drug development firm by Kaneka Eurogentec, an FDA-inspected CDMO specializing in injectable grade cGMP biopharmaceuticals. The accomplishment is noteworthy due to its high efficiency in yielding one kilogram of plasmid DNA in only one fermentation run.
  • In June 2024, GenScript Biotech Corporation is excited to announce the launch of the GenScript FLASH Gene service, an exceptionally fast sequence-to-plasmid (S2P) service. The company is known for its unrelenting innovation in synthetic biology and for offering the finest gene synthesis services in the industry. Our flagship product satisfies the urgent demand for gene constructions with unmatched speed, quality, and affordability.
  • In March 2024, the Charles River Laboratories International, Inc. Modular and Fast Track viral vector technology (tech) transfer frameworks will be available for download. Thanks to the company's methodical approach, which it developed using decades of experience as a viral vector CDMO, its viral vector center of excellence (CoE) in Maryland can have a smooth and rapid process transfer in as little as nine months.

Overview of U.S. Consignee and Shipper Data in the Viral Vector and Plasmid DNA Manufacturing Market

CONSIGNEE NAME SHIPPER NAME PRODUCT DESCRIPTION QUANTITY WEIGHT
WNHL INC TRIBEST DENTAL PRODUCTS CO LIMITED SALIVA EJECTOR DENTAL PAPER TRAY DENTAL BIB 1870 7160
ASP GLOBAL LLC ZHEJIANG RUNLAB TECHNOLOGY CO LIMITED STERILE DISPOSABLE CENTRIFUGE TUBE 543 4438
BAUSCH AND LOMB JANSSEN PHARMACEUTICA NV J AND J PHARMA PHARMACEUTICALS 20 3414
GOFLY CARGO ALI ASSOCIAZIONE LATINOAMERICA HUMANITARIAN AID 153 3045
DARBY DENTAL SUPPLY LLC EURONDA DENTAL SUPPLIES 23 12101